{"id":2551,"date":"2018-02-16T17:52:08","date_gmt":"2018-02-16T12:22:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2551"},"modified":"2021-07-24T12:56:56","modified_gmt":"2021-07-24T07:26:56","slug":"notizia-pharma-news","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news","title":{"rendered":"Symdeko\u2019s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Vertex pharmaceutical\u2019s growth story in biotech with Symdeko\u2019s approval<\/strong><\/p>\n<p style=\"text-align: justify;\">FDA has recently approved Vertex Pharmaceutical\u2019s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko&#8217;s annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaftor, with the active ingredient in Kalydeco, ivacaftor. Vertex assumes that the combo will get the approval &amp; Orkambi\u2019s uptake will grow gradually.<\/p>\n<p style=\"text-align: justify;\"><strong>Erytech targeting solid tumors through Red blood cell-encapsulated drug therapy<\/strong><\/p>\n<p style=\"text-align: justify;\">Disappointed from the leukemia data French biotech Erytech is now refocusing on its red blood cell-encapsulated drug therapy to target solid tumors. It will most likely target triple-negative breast cancer in its next trial. The company is getting ready for a phase 2 study of Graspa (red-cell encapsulated L-asparaginase or eryaspase) in TNBC. It will be the second solid tumor indication for the therapy after metastatic pancreatic cancer, company hopes to have the trial underway in the third quarter this year.<\/p>\n<p style=\"text-align: justify;\"><strong>Oncologie snapped up bavituximab and other assets from Avid<\/strong><\/p>\n<p style=\"text-align: justify;\">In a recent deal, Oncologie Inc. has snapped up Avid\u2019s (CDMO) bavituximab and other phosphatidylserine-targeting assets. As per the deal, Oncologie will be responsible for the research, development, and commercialization of bavituximab and Avid will carry out the contract development and manufacturing activities.<\/p>\n<p style=\"text-align: justify;\"><strong>Merck delivers latest Alzheimer&#8217;s disappointment<\/strong><\/p>\n<p style=\"text-align: justify;\">Merck has announced the termination of another phase 3 study for Alzheimer treatment verubecestat (MK-8931). The reason for the latest termination is an external Data monitoring committee according to which the treatment will not have any positive result.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vertex pharmaceutical\u2019s growth story in biotech with Symdeko\u2019s approval FDA has recently approved Vertex Pharmaceutical\u2019s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko&#8217;s annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaftor, with the active ingredient in Kalydeco, ivacaftor. Vertex assumes that the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1407,1403,1405,1404,204,1400,1399,1398,349,381,395,1402,1230,1196,749,1406,1401,1396,1397,1395,1408],"industry":[17225],"therapeutic_areas":[17238,17245,17228],"class_list":["post-2551","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimer","tag-avid","tag-bavituximab","tag-cdmo","tag-delveinsight","tag-graspa","tag-ivacaftor","tag-kalydeco","tag-latest-pharma-news","tag-market-research","tag-merck","tag-oncologie","tag-pharma-consultancy","tag-pharma-research","tag-pharmaceutical-market","tag-phosphatidylserine-targeting","tag-red-cell-encapsulated-l-asparaginase-or-eryaspase","tag-symdeko","tag-tezacaftor","tag-vertex-pharmaceutical","tag-verubecestat","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Symdeko\u2019s FDA approval; Erytech target solid tumors<\/title>\n<meta name=\"description\" content=\"FDA has recently approved Vertex Pharmaceutical\u2019s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Symdeko\u2019s FDA approval; Erytech target solid tumors\" \/>\n<meta property=\"og:description\" content=\"FDA has recently approved Vertex Pharmaceutical\u2019s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-16T12:22:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Symdeko\u2019s FDA approval; Erytech target solid tumors","description":"FDA has recently approved Vertex Pharmaceutical\u2019s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news","og_locale":"en_US","og_type":"article","og_title":"Symdeko\u2019s FDA approval; Erytech target solid tumors","og_description":"FDA has recently approved Vertex Pharmaceutical\u2019s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population.","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-02-16T12:22:08+00:00","article_modified_time":"2021-07-24T07:26:56+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news","url":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news","name":"Symdeko\u2019s FDA approval; Erytech target solid tumors","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-02-16T12:22:08+00:00","dateModified":"2021-07-24T07:26:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"FDA has recently approved Vertex Pharmaceutical\u2019s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Avid<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">bavituximab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CDMO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Graspa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ivacaftor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kalydeco<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Oncologie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">phosphatidylserine-targeting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">red-cell encapsulated L-asparaginase or eryaspase<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Symdeko<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">tezacaftor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vertex pharmaceutical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">verubecestat<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer<\/span>","<span class=\"advgb-post-tax-term\">Avid<\/span>","<span class=\"advgb-post-tax-term\">bavituximab<\/span>","<span class=\"advgb-post-tax-term\">CDMO<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Graspa<\/span>","<span class=\"advgb-post-tax-term\">ivacaftor<\/span>","<span class=\"advgb-post-tax-term\">Kalydeco<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Oncologie<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma research<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Market<\/span>","<span class=\"advgb-post-tax-term\">phosphatidylserine-targeting<\/span>","<span class=\"advgb-post-tax-term\">red-cell encapsulated L-asparaginase or eryaspase<\/span>","<span class=\"advgb-post-tax-term\">Symdeko<\/span>","<span class=\"advgb-post-tax-term\">tezacaftor<\/span>","<span class=\"advgb-post-tax-term\">Vertex pharmaceutical<\/span>","<span class=\"advgb-post-tax-term\">verubecestat<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 16, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 16, 2018 5:52 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2551"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2551\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2551"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2551"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}